Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

被引：0

作者：

Mai, Hai-Qiang ^{[1
]}

Chen, Qiu-Yan ^{[1
]}

Chen, Dongping ^{[2
]}

Hu, Chaosu ^{[3
]}

Yang, Kunyu ^{[4
]}

Wen, Jiyu ^{[5
]}

Li, Jingao ^{[6
]}

Shi, Yingrui ^{[7
,8
]}

Jin, Feng ^{[9
]}

Xu, Ruilian ^{[10
]}

Pan, Jianji ^{[11
]}

Qu, Shenhong ^{[12
]}

Li, Ping ^{[13
]}

Hu, Chunhong ^{[14
]}

Liu, Yi-Chun ^{[15
]}

Jiang, Yi ^{[16
]}

He, Xia ^{[17
]}

Wang, Hung-Ming ^{[18
]}

Lim, Wan-Teck ^{[19
]}

Xu, Rui-Hua ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[2] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China

[3] Fudan Univ, Ctr Canc, Shanghai, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[5] Affiliated Hosp Guangdong Med Univ, Zhanjiang, Peoples R China

[6] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China

[7] Xiangya Sch Med, Hunan Canc Hosp, Changsha, Peoples R China

[8] Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China

[9] Guizhou Med Univ, Guizhou Canc Hosp, Guiyang, Peoples R China

[10] Shenzhen Peoples Hosp, Shenzhen, Peoples R China

[11] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[12] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China

[13] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[14] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China

[15] Taichung Vet Gen Hosp, Taichung, Taiwan

[16] Canc Hosp Shantou Univ, Coll Med, Shantou, Peoples R China

[17] Jiangsu Canc Hosp, Nanjing, Peoples R China

[18] Chang Gung Mem Hosp, Taoyuan, Taiwan

[19] Natl Canc Ctr, Singapore, Singapore

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT226

引用

页数：2

共 50 条

[41] Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Wang, Jie
Wang, Zhijie
Wu, Lin
Li, Baolan
Cheng, Ying
Li, Xiaoling
Wang, Xicheng
Han, Liang
Wu, Xiaohong
Fan, Yun
Yu, Yan
Lv, Dongqing
Shi, Jianhua
Huang, Jianjin
Zhou, Shaozhang
Han, Baohui
Sun, Guogui
Guo, Qisen
Ji, Youxin
Zhu, Xiaoli
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Yoon, H.
Kato, K.
Raymond, E.
Hubner, R.
Shu, Y.
Pan, Y.
Jiang, Y.
Zhang, J.
Park, S.
Kojima, T.
Lin, C.
Gotovkin, E.
Wyrwicz, L.
Ishihara, R.
Li, L.
Tao, A.
Shi, J.
Wang, L.
Xu, J.
ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375
[43] Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Monk, Bradley
Tewari, Krishnansu
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Nguyen, Allison Martin
Monberg, Matthew
Colombo, Nicoletta
Lorusso, Domenica
GYNECOLOGIC ONCOLOGY, 2022, 166 : S18 - S18
[44] Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
Raunkilde, Louise
Hansen, Torben Frostrup
Havelund, Birgitte Mayland
Thomsen, Caroline Brenner
Rafaelsen, Soren Rafael
Lindebjerg, Jan
Jensen, Lars Henrik
ACTA ONCOLOGICA, 2023, 62 (09) : 1066 - 1075
[45] Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non-Small-Cell Lung Cancer
Jaenne, Pasi A.
Paz-Ares, Luis
Oh, Yun
Eschbach, Corinna
Hirsh, Vera
Enas, Nathan
Brail, Leslie
von Pawel, Joachim
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) : 126 - 131
[46] Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC)
Miles, D. W.
Chan, A.
Romieu, G.
Dirix, L.
Cortes, J.
Pivot, X.
Tomczak, P.
Juozaityte, E.
Harbeck, N.
Steger, G. G.
CANCER RESEARCH, 2009, 69 (24) : 495S - 495S
[47] First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
Yan Song
Bo Zhang
Dao Xin
Xiaoge Kou
Zhenbo Tan
Shu Zhang
Meili Sun
Jin Zhou
Min Fan
Ming Zhang
Yongxiang Song
Suyi Li
Yuan Yuan
Wu Zhuang
Jingdong Zhang
Li Zhang
Hao Jiang
Kangsheng Gu
Huangyang Ye
Ying Ke
Jing Li
Qingyu Wang
Jun Zhu
Jing Huang
Nature Medicine, 2023, 29 : 473 - 482
[48] First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
Song, Yan
Zhang, Bo
Xin, Dao
Kou, Xiaoge
Tan, Zhenbo
Zhang, Shu
Sun, Meili
Zhou, Jin
Fan, Min
Zhang, Ming
Song, Yongxiang
Li, Suyi
Yuan, Yuan
Zhuang, Wu
Zhang, Jingdong
Zhang, Li
Jiang, Hao
Gu, Kangsheng
Ye, Huangyang
Ke, Ying
Li, Jing
Wang, Qingyu
Zhu, Jun
Huang, Jing
NATURE MEDICINE, 2023, 29 (02) : 473 - 482
[49] Final Progression-free survival interim overall survival, and biomarker analyses of CHOICE-01: A Phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations
Wang, Jie
Wang, Zhijie
Wu, Lin
Li, Baolan
Cheng, Ying
Li, Xiaoling
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
[50] Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve
Gross-Goupil, Marine
Domblides, Charlotte
Lefort, Felix
Ravaud, Alain
BULLETIN DU CANCER, 2020, 107 (05) : ES1 - ES7

← 1 2 3 4 5 →